MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) announced today that it has completed a phase 1 trial of the Company’s medical countermeasure for acute radiation syndrome (ARS), BIO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback